Dotmatics”企业科学平台< / > < / span > <你> < span lang =“EN”> < / span > < / u > < span lang =“EN”>先进,抗体发现实验室常用的应用软件包括< a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQblJt " target = "平等" > < / > < a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQbmJD " target = "平等" > Geneious < / >、< a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQblJt " target = "平等" > SnapGene < / >、< a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQbmJD " target = "平等" > < / >和< a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQb0JN " target = "平等" > < / > < a href = " http://tvfri.tsmtpgaze.com/tracking/qaR9ZGLmZwpjBGL4AQHlZGL4BGN4BPM5qzS4qaR9ZQb0JN " target = "平等" > GraphPad棱镜< / >。完全集成的解决方案将简化抗体发现的数据收集和处理工作流程,促进的途径更有效和高效的发现,和加速进展可能改变治疗病人。< / span > < / p > < p > < span lang =“EN”> < br > < / span > < b > <我> < span lang =“EN”>“< / span > < / i > < / b > <我> < span lang =“EN”> Dotmatics生物抗体发现解决方案的推出是抗体的行业首个真正的端到端解决方案创新工作流和代表一个巨大的进步在抗体的发现,”< / span > < / i > < span lang =“EN”> < b >迈克·麦基说,总统Dotmatics < / b > <我>。“无论是R& D生物或化学或配方,Dotmatics帮助科学家和他们的组织协调数据科学与科学数据。" < / i > < / span > < / p > < p > < span lang =“EN”> <我> < br > < / i > < / span >发现研究数据在一个孤立的企业和本地系统仍然是一个至关重要的药物发现研究人员面临的挑战。比利时罗马尼亚比分直播科学家们被迫妥协的速度或准确性。与许多断开工作流通常是手工数据处理,结果导致数据错误和效率低下的风险。< br > < / p > < p > < / p > < p > Dotmatics抗体工作流支持的广度抗体发现通过解决这些问题,给组织一个基于云的数据管理平台集中,充分结合证明科学应用和生产力工具,最终用户的信任。至关重要的是,它自动操作手册,容易出错的任务和数据集中数据管理帮助组织作出更明智的决定,并最终加速抗体的研究。< br > < / p > < p > < / p > < p >抗体增长研究战斗慢性疾病抗体疗法的目的是突出的预计投资市场。 A 2022 research report by Future Market Insights projected that the antibody therapy market is expected to reach $700 billion by 2032, up from $186 billion. Another report by the Insight Partners projects that the global monoclonal antibody market will reach $243 billion by 2028 from $111 billion in 2021.

“As scientists pursue critical antibody therapies to fight disease, Dotmatics is connecting them with their data in ways that accelerate innovation and help make the world a healthier, cleaner, safer place to live,” said Michael Swartz, senior vice president of enterprise product at Dotmatics. “We are at the forefront of a digital transformation in the scientific R&D industry with an emphasis on providing researchers end-to-end solutions with connected data and workflows. They should be able to use the tools they know and love, while still centralizing data in order to satisfy the needs of the organization.”  

The Dotmatics antibody workflow incorporates FAIR data practices and provides a uniquely broad and deep solution traversing early candidate selection through cycles of innovation to provide highly refined antibody candidates to progress into animal trial and translational medicine.

  

">